Why Is Capricor Therapeutics, Inc. (CAPR) Stock Down -12% Today?
Key Takeaways
- CAPR shares fell approximately 11.5% intraday amid heightened regulatory scrutiny.
- The primary catalyst was the FDA’s announcement scheduling an advisory committee meeting for Deramiocel’s Biologics License Application.
- Positive five-year clinical data for the Duchenne muscular dystrophy therapy failed to offset investor concerns over the upcoming review.
- Broader biotech sector weakness and profit-taking after recent gains amplified the decline.
- Traders are now focused on the July 29 advisory committee meeting and the August 22 PDUFA target action date.
Opening Summary
Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for rare diseases, with its lead candidate Deramiocel targeting cardiomyopathy associated with Duchenne muscular dystrophy. Shares declined sharply in today’s session, falling roughly 11.5% from the prior close of $29.51 to trade near $26.91. The move reflects market reaction to fresh regulatory developments rather than a change in the company’s fundamental clinical progress.
**
Regulatory Catalyst: FDA Advisory Committee Meeting
The U.S. Food and Drug Administration scheduled an advisory committee meeting for July 29, 2026, to review Capricor’s Biologics License Application for Deramiocel. While such meetings provide an opportunity to present data, they also introduce an additional layer of public scrutiny and potential for debate on clinical endpoints. Investors interpreted the announcement as a signal of heightened review intensity ahead of the August 22, 2026 PDUFA target action date, triggering immediate selling pressure despite the company’s recent presentation of positive five-year open-label extension data from the HOPE-2 trial and Phase 3 HOPE-3 results.
**
Clinical Data Context and Market Reaction
Capricor simultaneously highlighted encouraging long-term muscle and cardiac function outcomes at the PPMD 2026 Annual Conference. However, the regulatory milestone overshadowed the positive clinical updates. The stock’s sharp reversal illustrates how binary regulatory events can dominate price action even when underlying trial results remain supportive. Volume increased notably compared with recent averages, indicating broad participation in the move.
Market Context and Trading Activity
The decline occurred against a backdrop of mixed broader biotech performance and modest gains in major indices. CAPR decoupled from sector peers as the company-specific news dominated sentiment. Technical levels near recent highs gave way, with the stock breaking below short-term moving averages amid the selloff. Elevated trading activity relative to the 30-day average confirmed the move carried conviction rather than reflecting thin liquidity.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform’s strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-driven trading bots across thousands of symbols and strategies, but only those demonstrating the best risk-adjusted performance metrics in the prevailing environment are featured in the curated Trending section. Bots differ by time horizon, signal generation approach, and the specific equities or assets they trade. Investors seeking automated, data-driven exposure to names such as CAPR can explore the live rankings and performance statistics on the page.
What Comes Next for CAPR
Attention now turns to the July 29 advisory committee meeting and any additional information requests from the FDA ahead of the August 22 PDUFA date. The company continues to advance manufacturing preparations and address commercial considerations, including an ongoing legal matter with its former distributor that does not affect the regulatory timeline. Key risks include the outcome of the advisory vote, potential labeling limitations, and overall market volatility in the biotechnology sector. No material changes to the review clock have been indicated to date.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CAPR's RSI Oscillator ascends from oversold territory
The RSI Indicator for CAPR moved out of oversold territory on June 12, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In of the 29 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 17, 2026. You may want to consider a long position or call options on CAPR as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CAPR just turned positive on June 17, 2026. Looking at past instances where CAPR's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
CAPR moved above its 50-day moving average on June 25, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CAPR broke above its upper Bollinger Band on June 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CAPR entered a downward trend on June 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.098) is normal, around the industry mean (20.978). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). CAPR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (125.000) is also within normal values, averaging (367.072).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology